Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
PROTACs Targeting MLKL Protect Cells from Necroptosis
Rathje, Oliver H. ; Perryman, Lara ; Payne, Richard J. , et al. J. Med. Chem.,2023,66(16):11216-11236. DOI: 10.1021/acs.jmedchem.3c00665 PubMed ID: 37535857
More
Abstract: Mixed Lineage Kinase domain-Like pseudokinase (MLKL) is implicated in a broad range of diseases due to its role as the ultimate effector of necroptosis and has therefore emerged as an attractive drug target. Here, we describe the development of PROteolysis TArgeting Chimeras (PROTACs) as a novel approach to knock down MLKL through chem. means. A series of candidate degraders were synthesized from a high-affinity pyrazole carboxamide-based MLKL ligand leading to the identification of a PROTAC mol. that effectively degraded MLKL and completely abrogated cell death in a TSZ model of necroptosis. By leveraging the innate ability of these PROTACs to degrade MLKL in a dose-dependent manner, the quant. relationship between MLKL levels and necroptosis was interrogated. This work demonstrates the feasibility of targeting MLKL using a PROTAC approach and provides a powerful tool to further our understanding of the role of MLKL within the necroptotic pathway.
Purchased from AmBeed: 30100-16-4 ; 4530-20-5 ; 1703808-53-0 ; 2840-26-8 ; 234081-98-2 ; 108466-89-3 ; 1005342-46-0 ; 154775-43-6 ; 214360-73-3 ; 31108-57-3 ; 57294-38-9 ; 234081-98-2 ; 73183-34-3 ; 462100-06-7 ; 187389-52-2 ; 191732-72-6 ; 173405-78-2 ; 154590-35-9 ; 6404-29-1 ; 1807518-63-3 ; 62595-74-8 ; 77383-17-6 ; 1310949-97-3 ; 138563-69-6 ; 138563-68-5 ; 2704620-74-4 ; 2284453-73-0 ; 191732-72-6 ; 181073-79-0 ...More
CAS No. : | 4530-20-5 | MDL No. : | MFCD00002690 |
Formula : | C7H13NO4 | Boiling Point : | - |
Linear Structure Formula : | (CH3)3COC(O)NHCH2C(O)OH | InChI Key : | VRPJIFMKZZEXLR-UHFFFAOYSA-N |
M.W : | 175.18 | Pubchem ID : | 78288 |
Synonyms : |
|
Signal Word: | Danger | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338-P310-P403-P501 | UN#: | N/A |
Hazard Statements: | H318 | Packing Group: | N/A |
GHS Pictogram: |
A491114[ 97352-64-2 ]
N-(tert-butoxycarbonyl)glycine-1-13c
Reason: Stable Isotope
A158054[ 145143-02-8 ]
N-(tert-butoxycarbonyl)glycine-2-13c
Reason: Stable Isotope
A418158[ 145143-01-7 ]
N-(tert-butoxycarbonyl)glycine-2-13c-15n
Reason: Stable Isotope
[ 14719-37-0 ]
ethyl 2-((tert-Butoxycarbonyl)amino)acetate
Similarity: 0.93
[ 13734-36-6 ]
N-(tert-Butoxycarbonyl)-N-methylglycine
Similarity: 0.91